|
US20030225254A1
(en)
*
|
1989-08-07 |
2003-12-04 |
Rathjen Deborah Ann |
Tumour necrosis factor binding ligands
|
|
US5959087A
(en)
*
|
1989-08-07 |
1999-09-28 |
Peptide Technology, Ltd. |
Tumour necrosis factor binding ligands
|
|
JP3443119B2
(ja)
*
|
1989-08-07 |
2003-09-02 |
ペプテック リミテッド |
腫瘍壊死因子結合リガンド
|
|
US7192584B2
(en)
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
|
US6270766B1
(en)
|
1992-10-08 |
2001-08-07 |
The Kennedy Institute Of Rheumatology |
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
|
|
ZA95960B
(en)
*
|
1994-03-14 |
1995-10-10 |
Genetics Inst |
Use of interleukin-12 antagonists in the treatment of autoimmune diseases
|
|
US6706264B1
(en)
*
|
1994-03-14 |
2004-03-16 |
Genetics Institute, Llc |
Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
|
|
US20010055581A1
(en)
|
1994-03-18 |
2001-12-27 |
Lawrence Tamarkin |
Composition and method for delivery of biologically-active factors
|
|
US6090382A
(en)
*
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
DE69721548T2
(de)
*
|
1996-02-09 |
2004-04-01 |
Abbott Laboratories(Bermuda)Ltd. |
HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
|
|
US7129061B1
(en)
*
|
1996-08-07 |
2006-10-31 |
Biogen Idec Ma Inc. |
Tumor necrosis factor related ligand
|
|
US20040009166A1
(en)
*
|
1997-04-30 |
2004-01-15 |
Filpula David R. |
Single chain antigen-binding polypeptides for polymer conjugation
|
|
WO1998048837A1
(en)
*
|
1997-04-30 |
1998-11-05 |
Enzon, Inc. |
Polyalkylene oxide-modified single chain polypeptides
|
|
US7229841B2
(en)
|
2001-04-30 |
2007-06-12 |
Cytimmune Sciences, Inc. |
Colloidal metal compositions and methods
|
|
US6407218B1
(en)
|
1997-11-10 |
2002-06-18 |
Cytimmune Sciences, Inc. |
Method and compositions for enhancing immune response and for the production of in vitro mabs
|
|
US7067144B2
(en)
*
|
1998-10-20 |
2006-06-27 |
Omeros Corporation |
Compositions and methods for systemic inhibition of cartilage degradation
|
|
US7553487B2
(en)
|
1998-12-14 |
2009-06-30 |
Genetics Institute, Llc |
Method and compositions for treating asthma
|
|
ES2277460T3
(es)
|
1998-12-14 |
2007-07-01 |
Genetics Institute, Llc |
Cadena del receptor de la citoquina.
|
|
JP2002538170A
(ja)
*
|
1999-03-02 |
2002-11-12 |
セントコール， インコーポレイテッド |
喘息の治療における抗−ＴＮＦα抗体
|
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
|
US20040220103A1
(en)
|
1999-04-19 |
2004-11-04 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
|
WO2001024827A2
(en)
*
|
1999-10-06 |
2001-04-12 |
Basf Aktiengesellschaft |
INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND αVβ3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY
|
|
CA2399148A1
(en)
|
2000-02-10 |
2001-08-16 |
Abbott Laboratories |
Antibodies that bind human interleukin-18 and methods of making and using
|
|
GB0013810D0
(en)
|
2000-06-06 |
2000-07-26 |
Celltech Chiroscience Ltd |
Biological products
|
|
EP2386575A3
(en)
|
2000-06-29 |
2011-11-30 |
Abbott Laboratories |
Dual specificity antibodies and methods of making and using
|
|
UA81743C2
(uk)
*
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
|
US20050196755A1
(en)
*
|
2000-11-17 |
2005-09-08 |
Maurice Zauderer |
In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
|
|
JP4986370B2
(ja)
|
2000-12-22 |
2012-07-25 |
マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ |
Ｒｇｍおよびそのモジュレーターの用途
|
|
US20090137416A1
(en)
|
2001-01-16 |
2009-05-28 |
Regeneron Pharmaceuticals, Inc. |
Isolating Cells Expressing Secreted Proteins
|
|
US6919183B2
(en)
*
|
2001-01-16 |
2005-07-19 |
Regeneron Pharmaceuticals, Inc. |
Isolating cells expressing secreted proteins
|
|
US7795494B2
(en)
|
2001-03-22 |
2010-09-14 |
Abbott Laboratories |
Transgenic mice expressing antibodies specific for genes of interest and uses thereof
|
|
US6410955B1
(en)
*
|
2001-04-19 |
2002-06-25 |
Micron Technology, Inc. |
Comb-shaped capacitor for use in integrated circuits
|
|
CA2868614A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
|
EP1414517A4
(en)
*
|
2001-06-26 |
2008-02-06 |
Photomed Technologies Inc |
MULTIPLE WAVELENGTH ILLUMINATOR
|
|
ES2706902T3
(es)
|
2001-06-26 |
2019-04-01 |
Amgen Inc |
Anticuerpos para OPGL
|
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
|
TWI334439B
(en)
|
2001-08-01 |
2010-12-11 |
Centocor Inc |
Anti-tnf antibodies, compositions, methods and uses
|
|
WO2003024384A2
(en)
*
|
2001-09-20 |
2003-03-27 |
Magnum Therapeutics |
Improved methods for treatment with viral vectors
|
|
US20030065382A1
(en)
*
|
2001-10-02 |
2003-04-03 |
Fischell Robert E. |
Means and method for the treatment of coronary artery obstructions
|
|
EP3254687A1
(en)
|
2001-10-04 |
2017-12-13 |
Genetics Institute LLC |
Methods and compositions for modulating interleukin-21 receptor activity
|
|
US20040018195A1
(en)
*
|
2002-03-26 |
2004-01-29 |
Griswold Don Edgar |
Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
|
|
US20040009172A1
(en)
*
|
2002-04-26 |
2004-01-15 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
|
US20030206898A1
(en)
*
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
|
US20090280065A1
(en)
*
|
2006-04-10 |
2009-11-12 |
Willian Mary K |
Uses and Compositions for Treatment of Psoriasis
|
|
CN101745112A
(zh)
*
|
2002-07-19 |
2010-06-23 |
艾博特生物技术有限公司 |
TNFα相关疾病的治疗
|
|
US20040033228A1
(en)
*
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
AU2003265361A1
(en)
*
|
2002-08-28 |
2004-03-19 |
Pharmacia Corporation |
Stable ph optimized formulation of a modified antibody
|
|
MY150740A
(en)
*
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
|
EP3299393A1
(en)
|
2002-11-08 |
2018-03-28 |
Ablynx N.V. |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
|
US20060034845A1
(en)
|
2002-11-08 |
2006-02-16 |
Karen Silence |
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
|
|
US20040162414A1
(en)
*
|
2002-11-22 |
2004-08-19 |
Santora Ling C. |
Method for reducing or preventing modification of a polypeptide in solution
|
|
US20040101939A1
(en)
*
|
2002-11-22 |
2004-05-27 |
Santora Ling C. |
Method for reducing or preventing modification of a polypeptide in solution
|
|
JP4754219B2
(ja)
|
2002-12-02 |
2011-08-24 |
アムジエン・フレモント・インコーポレイテツド |
腫瘍壊死因子を対象とする抗体、およびそれらの使用
|
|
AU2003299971A1
(en)
*
|
2002-12-30 |
2004-07-29 |
Amgen Inc. |
Combination therapy with co-stimulatory factors
|
|
WO2004063335A2
(en)
*
|
2003-01-08 |
2004-07-29 |
Applied Molecular Evolution |
TNF-α BINDING MOLECULES
|
|
US7101978B2
(en)
*
|
2003-01-08 |
2006-09-05 |
Applied Molecular Evolution |
TNF-α binding molecules
|
|
NZ540771A
(en)
*
|
2003-01-10 |
2009-05-31 |
Ablynx Nv |
Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
JP4914209B2
(ja)
|
2003-03-14 |
2012-04-11 |
ワイス |
ヒトｉｌ−２１受容体に対する抗体および該抗体の使用
|
|
EP1460088A1
(en)
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanized anti-CD4 antibody with immunosuppressive properties
|
|
WO2004098578A2
(en)
*
|
2003-05-12 |
2004-11-18 |
Altana Pharma Ag |
Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
|
|
FR2856075B1
(fr)
*
|
2003-06-16 |
2007-10-12 |
Monoclonal Antibodies Therapeu |
Procede essentiellement automatise de criblage a grande echelle de cellules secretant des anticorps monoclonaux
|
|
FR2859725B1
(fr)
*
|
2003-09-16 |
2006-03-10 |
Neovacs |
Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
|
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
|
KR100772800B1
(ko)
*
|
2003-11-17 |
2007-11-01 |
주식회사유한양행 |
인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
|
|
EP1694301A4
(en)
|
2003-12-02 |
2009-11-18 |
Cytimmune Sciences Inc |
METHOD AND COMPOSITIONS FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES
|
|
PL1711528T3
(pl)
|
2003-12-23 |
2012-11-30 |
Genentech Inc |
Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13
|
|
US7435799B2
(en)
*
|
2004-01-08 |
2008-10-14 |
Applied Molecular Evolution |
TNF-α binding molecules
|
|
US7625549B2
(en)
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
|
WO2005092926A2
(en)
|
2004-03-19 |
2005-10-06 |
Amgen Inc. |
Reducing the risk of human and anti-human antibodies through v gene manipulation
|
|
TW201705980A
(zh)
|
2004-04-09 |
2017-02-16 |
艾伯維生物技術有限責任公司 |
用於治療ＴＮＦα相關失調症之多重可變劑量療法
|
|
CN100427504C
(zh)
*
|
2004-06-02 |
2008-10-22 |
北京天广实生物技术有限公司 |
TNFα高亲和力嵌合抗体及其用途
|
|
US7501121B2
(en)
|
2004-06-17 |
2009-03-10 |
Wyeth |
IL-13 binding agents
|
|
AR049390A1
(es)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
|
US20060039902A1
(en)
*
|
2004-08-05 |
2006-02-23 |
Young Deborah A |
Antagonizing interleukin-21 receptor activity
|
|
US20060083741A1
(en)
*
|
2004-10-08 |
2006-04-20 |
Hoffman Rebecca S |
Treatment of respiratory syncytial virus (RSV) infection
|
|
US7968308B2
(en)
*
|
2004-10-22 |
2011-06-28 |
Danisco Us Inc. |
Isolating human antibodies
|
|
JP2008520717A
(ja)
|
2004-11-19 |
2008-06-19 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
多発性硬化症についての処置
|
|
PT3520815T
(pt)
|
2005-02-08 |
2022-02-02 |
Genzyme Corp |
Anticorpos contra tgfbeta
|
|
TW200641353A
(en)
*
|
2005-02-14 |
2006-12-01 |
Wyeth Corp |
Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
|
|
US7704503B2
(en)
*
|
2005-02-14 |
2010-04-27 |
Wyeth Llc |
Use of IL-17F in diagnosis and therapy of airway inflammation
|
|
DK2529619T3
(en)
|
2005-02-17 |
2016-01-11 |
Biogen Ma Inc |
Treatment of neurological disorders
|
|
GT200600148A
(es)
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
|
CA2607697C
(en)
*
|
2005-05-10 |
2015-01-06 |
Biogen Idec Ma Inc. |
Treating and evaluating inflammatory disorders
|
|
AU2012254978C1
(en)
*
|
2005-05-16 |
2017-06-01 |
Abbvie Biotechnology Ltd |
Use of TNF inhibitor for treatment of erosive polyarthritis
|
|
BRPI0610058A2
(pt)
|
2005-05-16 |
2010-05-25 |
Abbott Biotech Ltd |
uso de inibidor de tnf para tratamento da poliartrite erosiva
|
|
EP1888789A2
(en)
*
|
2005-06-06 |
2008-02-20 |
Wyeth a Corporation of the State of Delaware |
Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
|
|
ES2424042T3
(es)
|
2005-06-07 |
2013-09-26 |
Esbatech - A Novartis Company Llc |
Anticuerpos estables y solubles que inhiben TNF±
|
|
EP1909831A4
(en)
|
2005-06-14 |
2013-02-20 |
Amgen Inc |
SELF-BUFFING PROTEIN FORMULATIONS
|
|
US20060286108A1
(en)
*
|
2005-06-16 |
2006-12-21 |
Bell Katherine A |
Topical compositions for the treatment of chronic wounds
|
|
JP2008543449A
(ja)
*
|
2005-06-17 |
2008-12-04 |
アボット・ラボラトリーズ |
変性脊椎疾患の改良型治療方法
|
|
US20070009602A1
(en)
*
|
2005-06-24 |
2007-01-11 |
Setton Lori A |
Direct drug delivery system based on thermally responsive biopolymers
|
|
US20070065912A1
(en)
|
2005-07-21 |
2007-03-22 |
Abbott Laboratories |
Multiple Gene Expression including sORF Constructs and Methods with Polyproteins, Pro-Proteins, and Proteolysis
|
|
TW200726776A
(en)
*
|
2005-07-29 |
2007-07-16 |
Friedrich Alexander University Of Erlangen Nuremberg |
CD33-specific single-chain immunotoxin and methods of use
|
|
EP2500353A3
(en)
|
2005-08-19 |
2012-10-10 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
TWI323734B
(en)
|
2005-08-19 |
2010-04-21 |
Abbott Lab |
Dual variable domain immunoglobulin and uses thereof
|
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
|
US20070041905A1
(en)
*
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP1928905B1
(de)
|
2005-09-30 |
2015-04-15 |
AbbVie Deutschland GmbH & Co KG |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
|
WO2007049286A1
(en)
*
|
2005-10-27 |
2007-05-03 |
Tata Memorial Centre |
A system for ex-vivo separation of apoptotic chromatin particles from blood or plasma
|
|
ES2431643T3
(es)
|
2005-11-01 |
2013-11-27 |
Abbvie Biotechnology Ltd |
Métodos para determinar la eficacia de adalimumab en sujetos que tienen espondilitis anquilosante utilizando CTX-II y MMP3 como biomarcadores
|
|
PE20070684A1
(es)
|
2005-11-14 |
2007-08-06 |
Amgen Inc |
MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
|
|
KR20080090408A
(ko)
|
2005-11-30 |
2008-10-08 |
아보트 러보러터리즈 |
항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
|
|
SG10201706600VA
(en)
|
2005-11-30 |
2017-09-28 |
Abbvie Inc |
Monoclonal antibodies and uses thereof
|
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
EP1971355B1
(en)
|
2005-12-20 |
2020-03-11 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
|
EA017417B1
(ru)
|
2006-02-01 |
2012-12-28 |
Сефалон Астралия Пти Лтд. |
КОНСТРУКТ ОДНОДОМЕННОГО АНТИТЕЛА, КОТОРЫЙ СВЯЗЫВАЕТСЯ С ЧЕЛОВЕЧЕСКИМ TNF-α, И ЕГО ПРИМЕНЕНИЕ
|
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
|
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
|
EP2738178A1
(en)
*
|
2006-04-05 |
2014-06-04 |
AbbVie Biotechnology Ltd |
Antibody purification
|
|
US9399061B2
(en)
|
2006-04-10 |
2016-07-26 |
Abbvie Biotechnology Ltd |
Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
|
|
EP2666479A3
(en)
|
2006-04-10 |
2014-03-26 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
|
US20080118496A1
(en)
*
|
2006-04-10 |
2008-05-22 |
Medich John R |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
|
EP2012586A4
(en)
|
2006-04-10 |
2010-08-18 |
Abbott Biotech Ltd |
USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS
|
|
US9624295B2
(en)
|
2006-04-10 |
2017-04-18 |
Abbvie Biotechnology Ltd. |
Uses and compositions for treatment of psoriatic arthritis
|
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
|
US20090317399A1
(en)
*
|
2006-04-10 |
2009-12-24 |
Pollack Paul F |
Uses and compositions for treatment of CROHN'S disease
|
|
US20080131374A1
(en)
*
|
2006-04-19 |
2008-06-05 |
Medich John R |
Uses and compositions for treatment of rheumatoid arthritis
|
|
US20100021451A1
(en)
*
|
2006-06-08 |
2010-01-28 |
Wong Robert L |
Uses and compositions for treatment of ankylosing spondylitis
|
|
US20080311043A1
(en)
*
|
2006-06-08 |
2008-12-18 |
Hoffman Rebecca S |
Uses and compositions for treatment of psoriatic arthritis
|
|
KR101440795B1
(ko)
|
2006-06-30 |
2014-09-22 |
애브비 바이오테크놀로지 리미티드 |
자동 주사 장치
|
|
MY161894A
(en)
|
2006-09-08 |
2017-05-15 |
Abbvie Bahamas Ltd |
Interleukin-13 binding proteins
|
|
EP2500413A1
(en)
*
|
2006-09-13 |
2012-09-19 |
Abbott Laboratories |
Cell culture improvements
|
|
EP2500416A1
(en)
|
2006-09-13 |
2012-09-19 |
Abbott Laboratories |
Cell culture improvements
|
|
US8911964B2
(en)
|
2006-09-13 |
2014-12-16 |
Abbvie Inc. |
Fed-batch method of making human anti-TNF-alpha antibody
|
|
KR20090101893A
(ko)
*
|
2006-10-27 |
2009-09-29 |
애보트 바이오테크놀로지 리미티드 |
결정형 항-ｈＴＮＦ알파 항체
|
|
CN101534824A
(zh)
|
2006-11-17 |
2009-09-16 |
艾博特公司 |
作为化学活素受体拮抗剂的氨基吡咯烷
|
|
CN105435223A
(zh)
|
2006-11-21 |
2016-03-30 |
卡罗拜奥斯制药公司 |
使用gm-csf拮抗剂治疗慢性炎症疾病的方法
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
US8324350B2
(en)
|
2006-12-29 |
2012-12-04 |
Abbott Laboratories |
Dual-specific IL-1α/IL-1β antibodies
|
|
US7776331B1
(en)
*
|
2007-01-16 |
2010-08-17 |
Abbott Laboratories |
Methods of treating plaque psoriasis
|
|
JP2008209378A
(ja)
*
|
2007-01-31 |
2008-09-11 |
Fujifilm Corp |
バイオセンサー基板
|
|
EP2148691B1
(en)
|
2007-02-05 |
2015-05-20 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
|
|
WO2008104386A2
(en)
|
2007-02-27 |
2008-09-04 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
|
RU2009137582A
(ru)
|
2007-03-12 |
2011-04-20 |
Эсбатек Аг (Ch) |
Инженерия и оптимизация одноцепочечных антител на основе последовательности
|
|
CL2008000883A1
(es)
*
|
2007-03-28 |
2008-10-03 |
Wyeth6 3 |
Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a
|
|
US7807168B2
(en)
*
|
2007-04-10 |
2010-10-05 |
Vaccinex, Inc. |
Selection of human TNFα specific antibodies
|
|
WO2008124858A2
(en)
*
|
2007-04-11 |
2008-10-23 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. |
Targeted receptor
|
|
EP2679995A1
(en)
|
2007-05-31 |
2014-01-01 |
AbbVie Inc. |
Biomarkers predictive of the responsiveness to TNF-alfa inhibitors in autoimmune disorders
|
|
EP2152318A4
(en)
*
|
2007-06-01 |
2011-12-07 |
Abbott Biotech Ltd |
COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
|
|
KR20100018040A
(ko)
*
|
2007-06-06 |
2010-02-16 |
도만티스 리미티드 |
프로테아제 내성 폴리펩티드를 선택하는 방법
|
|
BRPI0812398A2
(pt)
*
|
2007-06-06 |
2019-09-24 |
Domantis Ltd |
domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão
|
|
WO2008154543A2
(en)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis
|
|
AU2008266051B2
(en)
|
2007-06-14 |
2014-07-31 |
Biogen Ma Inc. |
Antibody formulations
|
|
BRPI0813645A2
(pt)
*
|
2007-06-25 |
2014-12-30 |
Esbatech Alcon Biomed Res Unit |
Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
|
|
EP2164961B1
(en)
*
|
2007-06-25 |
2015-01-07 |
ESBATech, an Alcon Biomedical Research Unit LLC |
Sequence based engineering and optimization of single chain antibodies
|
|
CN101848733A
(zh)
*
|
2007-07-13 |
2010-09-29 |
艾博特生物技术有限公司 |
用于肺部给予TNFα抑制剂的方法和组合物
|
|
SG183709A1
(en)
|
2007-08-08 |
2012-09-27 |
Abbott Lab |
Compositions and methods for crystallizing antibodies
|
|
EP3492488A1
(en)
|
2007-08-22 |
2019-06-05 |
The Regents of The University of California |
Activatable binding polypeptides and methods of identification and use thereof
|
|
EP2193145A4
(en)
|
2007-08-28 |
2011-05-18 |
Abbott Biotech Ltd |
COMPOSITIONS AND METHODS COMPRISING BINDING PROTEINS FOR ADALIMUMAB
|
|
JP2009082033A
(ja)
*
|
2007-09-28 |
2009-04-23 |
Kaneka Corp |
完全ヒト型抗体生産法
|
|
WO2009045370A2
(en)
|
2007-09-28 |
2009-04-09 |
Intrexon Corporation |
Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
|
|
EP2219458B1
(en)
|
2007-11-08 |
2015-07-15 |
Cytimmune Sciences, Inc. |
Compositions and methods for generating antibodies
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
TWI661833B
(zh)
|
2007-11-30 |
2019-06-11 |
百慕達商艾伯維生物技術有限責任公司 |
蛋白質調配物及製造其之方法
|
|
CN101965514A
(zh)
*
|
2008-01-03 |
2011-02-02 |
艾博特生物技术有限公司 |
预测化合物在治疗银屑病中的长期功效
|
|
NZ621174A
(en)
|
2008-01-15 |
2015-09-25 |
Abbvie Deutschland |
Powdered protein compositions and methods of making same
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
CA2718184A1
(en)
|
2008-03-13 |
2009-10-08 |
Biotest Ag |
Agent for treating disease
|
|
KR20100135807A
(ko)
|
2008-03-13 |
2010-12-27 |
바이오테스트 아게 |
질병 치료제
|
|
JP5604311B2
(ja)
|
2008-03-13 |
2014-10-08 |
バイオテスト・アクチエンゲゼルシヤフト |
疾患治療剤
|
|
NZ602511A
(en)
|
2008-03-18 |
2014-03-28 |
Abbvie Inc |
Methods for treating psoriasis
|
|
CN102076355B
(zh)
|
2008-04-29 |
2014-05-07 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
EP2113568A1
(en)
|
2008-04-30 |
2009-11-04 |
Deutsches Rheuma-Forschungszentrum Berlin |
Knock-in mouse for modelling blockade of human TNFalpha
|
|
KR101603917B1
(ko)
|
2008-05-09 |
2016-03-17 |
애브비 인코포레이티드 |
최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도
|
|
JPWO2009142186A1
(ja)
*
|
2008-05-20 |
2011-09-29 |
株式会社カネカ |
細胞障害性組成物
|
|
AU2009256246B2
(en)
|
2008-06-03 |
2013-07-18 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
SG191639A1
(en)
*
|
2008-06-03 |
2013-07-31 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
PT2307454T
(pt)
|
2008-06-25 |
2017-04-26 |
Esbatech Alcon Biomed Res Unit |
Anticorpos estáveis e solúveis que inibem o vegf
|
|
CA2728829C
(en)
|
2008-06-25 |
2018-01-02 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Solubility optimization of immunobinders
|
|
MX345039B
(es)
|
2008-06-25 |
2017-01-16 |
Esbatech Alcon Biomed Res Unit |
Anticuerpos estables y solubles que inhiben el tnfa.
|
|
JP2011526303A
(ja)
|
2008-06-27 |
2011-10-06 |
デューク ユニバーシティ |
エラスチン様ペプチドを含む治療剤
|
|
US20110177070A1
(en)
*
|
2008-07-02 |
2011-07-21 |
Emergent Product Development Seatlle, LLC |
TGF-Beta Antagonist Multi-Target Binding Proteins
|
|
BRPI0915825A2
(pt)
|
2008-07-08 |
2015-11-03 |
Abbott Lab |
proteínas de ligação à prostaglandina e2 usos das mesmas
|
|
AU2009268585C1
(en)
|
2008-07-08 |
2014-10-02 |
Abbvie Inc. |
Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
|
|
RU2011105466A
(ru)
*
|
2008-08-28 |
2012-10-10 |
ВАЙЕТ ЭлЭлСи (US) |
Применения цитокинов семейств il-22, il-17 и il-1 при аутоиммунных заболеваниях
|
|
EP2340039B1
(en)
*
|
2008-10-07 |
2015-11-25 |
National Cheng Kung University |
Use of il-20 antagonists for treating osteoporosis
|
|
EP3011953A1
(en)
|
2008-10-29 |
2016-04-27 |
Ablynx N.V. |
Stabilised formulations of single domain antigen binding molecules
|
|
EP2346900A1
(en)
|
2008-10-29 |
2011-07-27 |
Wyeth LLC |
Methods for purification of single domain antigen binding molecules
|
|
US8415291B2
(en)
|
2008-10-31 |
2013-04-09 |
Centocor Ortho Biotech Inc. |
Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
|
|
CN101419224B
(zh)
*
|
2008-11-06 |
2012-08-22 |
复旦大学附属华山医院 |
一种同时测定人血浆中霉酚酸酯、霉酚酸及其代谢物的方法
|
|
CN104398471A
(zh)
*
|
2008-11-28 |
2015-03-11 |
Abbvie公司 |
稳定的抗体组合物和用于稳定其的方法
|
|
CA2750155A1
(en)
|
2008-12-30 |
2010-07-08 |
Centocor Ortho Biotech Inc. |
Serum markers predicting clinical response to anti-tnf.alpha. antibodiesin patients with ankylosing spondylitis
|
|
CN101766602B
(zh)
*
|
2008-12-30 |
2012-01-11 |
中国医学科学院血液病医院（血液学研究所） |
取代芳香基腙类化合物在作为肿瘤坏死因子抑制剂药物方面的应用
|
|
WO2010081173A2
(en)
|
2009-01-12 |
2010-07-15 |
Cytomx Therapeutics, Llc |
Modified antibody compositions, methods of making and using thereof
|
|
AU2010215761B2
(en)
*
|
2009-02-23 |
2017-04-06 |
Cytomx Therapeutics, Inc |
Proproteins and methods of use thereof
|
|
US8030026B2
(en)
*
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
|
PE20160653A1
(es)
|
2009-03-05 |
2016-07-24 |
Abbvie Inc |
Proteinas de union a il-17
|
|
BRPI1012524A2
(pt)
*
|
2009-04-16 |
2020-09-29 |
Abbott Biotherapeutics Corp |
anticorpos anti-tnf-alfa e seus usos
|
|
CN101875694B
(zh)
*
|
2009-04-28 |
2014-04-02 |
中国医学科学院基础医学研究所 |
TNFα的抗体及其用途
|
|
US8636704B2
(en)
|
2009-04-29 |
2014-01-28 |
Abbvie Biotechnology Ltd |
Automatic injection device
|
|
NZ613809A
(en)
*
|
2009-05-04 |
2015-02-27 |
Abbvie Biotechnology Ltd |
Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
|
|
WO2010132872A1
(en)
*
|
2009-05-15 |
2010-11-18 |
Novimmune S.A |
Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists
|
|
TW201109438A
(en)
*
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
MX366935B
(es)
|
2009-08-14 |
2019-07-31 |
Phasebio Pharmaceuticals Inc |
Peptidos intestinales vasoactivos modificados.
|
|
BR112012008080A2
(pt)
*
|
2009-08-21 |
2017-07-04 |
Gilead Biologics Inc |
ensaios de rastreamento in vivo.
|
|
PE20121647A1
(es)
|
2009-08-29 |
2012-12-31 |
Abbvie Inc |
Proteinas terapeuticas de union a dll4
|
|
TW201119673A
(en)
|
2009-09-01 |
2011-06-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
KR20120112384A
(ko)
*
|
2009-09-14 |
2012-10-11 |
애보트 게엠베하 운트 콤파니 카게 |
건선을 치료하는 방법
|
|
EP2480252A4
(en)
*
|
2009-09-24 |
2014-04-30 |
Xbiotech Inc |
METHOD, COMPOSITIONS AND KITS FOR REDUCING ANTIBODY REACTIONS
|
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
|
EP3187877A1
(en)
|
2009-09-25 |
2017-07-05 |
XOMA Technology Ltd. |
Screening methods
|
|
UY32948A
(es)
|
2009-10-15 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
AU2010315547C1
(en)
*
|
2009-10-26 |
2015-06-04 |
Société des Produits Nestlé S.A. |
Assays for the detection of anti-TNF drugs and autoantibodies
|
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
TW201124535A
(en)
|
2009-10-30 |
2011-07-16 |
Abbott Lab |
SORF constructs and multiple gene expression
|
|
TW201121568A
(en)
|
2009-10-31 |
2011-07-01 |
Abbott Lab |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
|
US9244063B2
(en)
|
2009-11-11 |
2016-01-26 |
Gentian As |
Immunoassay for assessing related analytes of different origin
|
|
GB0920944D0
(en)
|
2009-11-30 |
2010-01-13 |
Biotest Ag |
Agents for treating disease
|
|
US8871208B2
(en)
*
|
2009-12-04 |
2014-10-28 |
Abbvie Inc. |
11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
|
|
KR20120118002A
(ko)
|
2009-12-08 |
2012-10-25 |
애보트 게엠베하 운트 콤파니 카게 |
망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
|
|
KR101780210B1
(ko)
|
2009-12-15 |
2017-09-21 |
애브비 바이오테크놀로지 리미티드 |
자동 주사 디바이스용 개선된 발사 버튼
|
|
WO2011075578A1
(en)
|
2009-12-16 |
2011-06-23 |
Philip Bosch |
Methods of treating interstitial cystitis
|
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
|
US9096655B2
(en)
|
2010-01-27 |
2015-08-04 |
Tata Memorial Centre |
Method for in-vivo binding of chromatin fragments
|
|
WO2011097301A2
(en)
|
2010-02-02 |
2011-08-11 |
Abbott Biotechnology Ltd. |
METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
|
|
CN102167741B
(zh)
*
|
2010-02-25 |
2014-05-14 |
上海百迈博制药有限公司 |
一种全人源抗TNF-α单克隆抗体、其制备方法及用途
|
|
SG10201501562VA
(en)
|
2010-03-02 |
2015-04-29 |
Abbvie Inc |
Therapeutic dll4 binding proteins
|
|
EP4450523A3
(en)
|
2010-04-02 |
2025-03-12 |
Amunix Pharmaceuticals, Inc. |
Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
|
|
BR112012025568A2
(pt)
|
2010-04-07 |
2017-03-28 |
Abbvie Inc |
proteínas de ligação ao tnf-<244>.
|
|
EP2558494B1
(en)
|
2010-04-15 |
2018-05-23 |
AbbVie Inc. |
Amyloid-beta binding proteins
|
|
PT2558499T
(pt)
|
2010-04-16 |
2017-07-14 |
Biogen Ma Inc |
Anticorpos anti-vla-4
|
|
CN104906656B
(zh)
|
2010-04-21 |
2020-01-10 |
艾伯维生物技术有限公司 |
用于治疗药剂的受控输送的可佩戴自动注射装置
|
|
EP2571532B1
(en)
|
2010-05-14 |
2017-05-03 |
Abbvie Inc. |
Il-1 binding proteins
|
|
WO2011146727A1
(en)
|
2010-05-19 |
2011-11-24 |
Philip Bosch |
Methods of treating interstitial cystitis
|
|
CN105056232A
(zh)
|
2010-06-03 |
2015-11-18 |
阿布维生物技术有限公司 |
用于治疗化脓性汗腺炎(hs)的用途和组合物
|
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
|
TW201206473A
(en)
|
2010-08-03 |
2012-02-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
US9062101B2
(en)
|
2010-08-14 |
2015-06-23 |
AbbVie Deutschland GmbH & Co. KG |
Amyloid-beta binding proteins
|
|
CA2808577C
(en)
|
2010-08-19 |
2018-09-25 |
Abbott Laboratories |
Anti-ngf antibodies and their use
|
|
CN103260639A
(zh)
|
2010-08-26 |
2013-08-21 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
|
AR083495A1
(es)
|
2010-10-22 |
2013-02-27 |
Esbatech Alcon Biomed Res Unit |
Anticuerpos estables y solubles
|
|
EP2632436B1
(en)
|
2010-10-29 |
2018-08-29 |
Abbvie Inc. |
Solid dispersions containing an apoptosis-inducing agent
|
|
UA113500C2
(xx)
|
2010-10-29 |
2017-02-10 |
|
Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
|
|
MX2013004979A
(es)
*
|
2010-11-02 |
2013-07-30 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
|
MX344727B
(es)
|
2010-11-11 |
2017-01-05 |
Abbvie Biotechnology Ltd |
Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
|
|
JP6141188B2
(ja)
|
2010-11-23 |
2017-06-07 |
アッヴィ・インコーポレイテッド |
アポトーシス誘導剤の塩および結晶の形態
|
|
NZ708508A
(en)
|
2010-11-23 |
2016-06-24 |
Abbvie Bahamas Ltd |
Methods of treatment using selective bcl-2 inhibitors
|
|
AR084210A1
(es)
*
|
2010-12-08 |
2013-05-02 |
Abbott Lab |
PROTEINAS DE UNION AL TNF-a
|
|
MY163368A
(en)
|
2010-12-21 |
2017-09-15 |
Abbvie Inc |
Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use
|
|
US20120275996A1
(en)
|
2010-12-21 |
2012-11-01 |
Abbott Laboratories |
IL-1 Binding Proteins
|
|
EP2490024A1
(en)
|
2010-12-22 |
2012-08-22 |
Proteomika, S.L. |
Method to optimize the treatment of patients with biological drugs
|
|
MX336571B
(es)
|
2011-01-24 |
2016-01-25 |
Elcam Medical Agricultural Cooperative Ass Ltd |
Inyector.
|
|
MY166835A
(en)
|
2011-01-24 |
2018-07-23 |
Abbvie Biotechnology Ltd |
Automatic injection devices having overmolded gripping surfaces
|
|
CN105709312B
(zh)
|
2011-01-24 |
2019-11-05 |
艾伯维生物技术有限公司 |
从注射器拆卸针罩和自动注射装置
|
|
RU2455025C1
(ru)
*
|
2011-02-10 |
2012-07-10 |
Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") |
Способ фармакологической коррекции ишемии конечности смесью растворов гомеопатических разведений
|
|
US20130344081A1
(en)
|
2011-03-07 |
2013-12-26 |
The University Of Tokushima |
Method of treating amyotrophic lateral sclerosis
|
|
JP2014511711A
(ja)
|
2011-03-18 |
2014-05-19 |
アッヴィ・インコーポレイテッド |
自動注入デバイスおよびそのサブアセンブリを組み立てるためのシステム、デバイス、および方法
|
|
TWI803876B
(zh)
|
2011-03-28 |
2023-06-01 |
法商賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
|
CN105413022A
(zh)
|
2011-03-29 |
2016-03-23 |
艾伯维公司 |
自动注射装置中的改进的护罩展开
|
|
CA2832729A1
(en)
|
2011-04-21 |
2012-10-26 |
Abbvie Inc. |
Wearable automatic injection device for controlled administration of therapeutic agents
|
|
EP2702077A2
(en)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
CN106432506A
(zh)
|
2011-05-24 |
2017-02-22 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
|
ES2729945T3
(es)
|
2011-05-31 |
2019-11-07 |
Biogen Ma Inc |
Procedimiento para valorar el riesgo de LMP
|
|
US9561262B2
(en)
|
2011-06-06 |
2017-02-07 |
Phasebio Pharmaceuticals, Inc. |
Use of modified vasoactive intestinal peptides in the treatment of hypertension
|
|
HK1198328A1
(zh)
|
2011-07-13 |
2015-04-02 |
Abbvie Inc. |
使用抗il-13抗體治療哮喘的方法和組合物
|
|
GB201112429D0
(en)
*
|
2011-07-19 |
2011-08-31 |
Glaxo Group Ltd |
Antigen-binding proteins with increased FcRn binding
|
|
EP2739650A4
(en)
*
|
2011-08-01 |
2015-04-01 |
Avaxia Biologics Inc |
SPECIFIC BOVINE POLYCLONAL ANTIBODY OF HUMAN TNF
|
|
TWI577696B
(zh)
*
|
2011-10-20 |
2017-04-11 |
Ｅｓｂａ科技 諾華有限責任公司 |
穩定的多重抗原結合抗體
|
|
UY34410A
(es)
|
2011-10-24 |
2013-05-31 |
Abbvie Inc |
Inmunoligantes biespecificos dirigidos contra tnf
|
|
JP2014533659A
(ja)
|
2011-10-24 |
2014-12-15 |
アッヴィ・インコーポレイテッド |
スクレロスチンに対するイムノバインダー
|
|
CN104093739A
(zh)
|
2011-10-24 |
2014-10-08 |
艾伯维公司 |
针对tnf的免疫结合剂
|
|
WO2013080050A2
(en)
|
2011-11-30 |
2013-06-06 |
Universitaetsklinikum Erlangen |
Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
|
|
JP6336397B2
(ja)
|
2011-12-14 |
2018-06-06 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
鉄関連障害を診断および治療するための組成物および方法
|
|
WO2013090635A2
(en)
|
2011-12-14 |
2013-06-20 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
|
WO2013087911A1
(en)
|
2011-12-16 |
2013-06-20 |
Synthon Biopharmaceuticals B.V. |
Compounds and methods for treating inflammatory diseases
|
|
US20130171059A1
(en)
|
2011-12-30 |
2013-07-04 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
WO2013102042A2
(en)
|
2011-12-30 |
2013-07-04 |
Abbvie Inc. |
Dual specific binding proteins directed against il-13 and/or il-17
|
|
PE20190907A1
(es)
|
2012-01-27 |
2019-06-26 |
AbbVie Deutschland GmbH and Co KG |
Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
|
|
SG11201405475UA
(en)
|
2012-03-07 |
2014-10-30 |
Cadila Healthcare Ltd |
Pharmaceutical formulations of tnf-alpha antibodies
|
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
|
EP2657334B1
(en)
|
2012-04-26 |
2016-07-06 |
GeneFrontier Corporation |
Efficient method for displaying protein multimer
|
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
|
AU2013271564A1
(en)
|
2012-06-06 |
2014-12-04 |
Zoetis Services Llc |
Caninized anti-NGF antibodies and methods thereof
|
|
SG11201408161RA
(en)
|
2012-06-08 |
2015-01-29 |
Sutro Biopharma Inc |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
|
WO2014011955A2
(en)
|
2012-07-12 |
2014-01-16 |
Abbvie, Inc. |
Il-1 binding proteins
|
|
ES2728864T3
(es)
|
2012-08-31 |
2019-10-29 |
Sutro Biopharma Inc |
Aminoácidos modificados que comprenden un grupo azido
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
BR112015004467A2
(pt)
|
2012-09-02 |
2017-03-21 |
Abbvie Inc |
método para controlar a heterogeneidade de proteínas
|
|
MX2015003007A
(es)
|
2012-09-07 |
2015-06-05 |
Coherus Biosciences Inc |
Formulaciones acuosas estables de adalimumab.
|
|
CN104704000A
(zh)
*
|
2012-09-19 |
2015-06-10 |
艾伯维生物医疗股份有限公司 |
识别具有降低免疫原性的抗体的方法
|
|
BR112015009924A2
(pt)
|
2012-11-01 |
2017-12-05 |
Abbvie Inc |
formulações de proteína imunoglobulina de domínio variável duplo estáveis
|
|
HK1212359A1
(en)
|
2012-11-01 |
2016-06-10 |
Abbvie Inc. |
Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
|
|
TWI675044B
(zh)
|
2012-11-14 |
2019-10-21 |
美商再生元醫藥公司 |
重組細胞表面捕捉蛋白質
|
|
WO2014100542A1
(en)
|
2012-12-21 |
2014-06-26 |
Abbvie, Inc. |
High-throughput antibody humanization
|
|
US9856319B2
(en)
|
2012-12-28 |
2018-01-02 |
Abbvie Inc. |
Monovalent binding proteins
|
|
WO2014106001A2
(en)
|
2012-12-28 |
2014-07-03 |
Abbvie, Inc. |
Dual specific binding proteins having a receptor sequence
|
|
KR101759687B1
(ko)
|
2013-01-25 |
2017-07-19 |
타이몬, 엘엘씨 |
순환하는 생물활성 가용성 tnf의 선택적 감소를 위한 조성물 및 tnf-매개 질환의 치료 방법
|
|
BR112015019341A2
(pt)
|
2013-02-13 |
2017-08-22 |
Lab Francais Du Fractionnement |
Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal
|
|
CA2905010A1
(en)
|
2013-03-12 |
2014-09-18 |
Abbvie Inc. |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
|
EP2970375A1
(en)
|
2013-03-14 |
2016-01-20 |
AbbVie Inc. |
Low acidic species compositions and methods for producing the same using displacement chromatography
|
|
US20140275082A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
|
WO2014158272A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbott Laboratories |
Hcv antigen-antibody combination assay and methods and compositions for use therein
|
|
CN105209616A
(zh)
|
2013-03-14 |
2015-12-30 |
雅培制药有限公司 |
用于改进的抗体检测的hcv ns3重组抗原及其突变体
|
|
CA2926384A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
WO2014143343A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbott Laboratories |
Hcv core lipid binding domain monoclonal antibodies
|
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
|
EP3424530A1
(en)
|
2013-03-15 |
2019-01-09 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
JP2016522793A
(ja)
|
2013-03-15 |
2016-08-04 |
アッヴィ・インコーポレイテッド |
ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
|
|
WO2014144299A2
(en)
|
2013-03-15 |
2014-09-18 |
Abbvie Inc. |
DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST TNFα
|
|
JP2016520595A
(ja)
*
|
2013-05-22 |
2016-07-14 |
メタボリック エンジニアリング ラボラトリーズ カンパニー リミテッド |
抗ＴＮＦ−α／ＣＸＣＬ１０二重ターゲット抗体及びその用途
|
|
WO2014197885A2
(en)
|
2013-06-07 |
2014-12-11 |
Duke University |
Inhibitors of complement factor h
|
|
ES2658039T3
(es)
|
2013-07-10 |
2018-03-08 |
Sutro Biopharma, Inc. |
Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
|
|
US20150038454A1
(en)
*
|
2013-07-31 |
2015-02-05 |
Mary Malast |
Antimicrobial compositions and methods of use
|
|
CN105722532A
(zh)
|
2013-09-13 |
2016-06-29 |
豪夫迈·罗氏有限公司 |
包含纯化的重组多肽的方法和组合物
|
|
BR112016004437A2
(pt)
|
2013-09-13 |
2017-10-17 |
Genentech Inc |
métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
|
|
US9598667B2
(en)
|
2013-10-04 |
2017-03-21 |
Abbvie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
|
WO2015051379A2
(en)
|
2013-10-06 |
2015-04-09 |
Abbvie Inc. |
Dual specific binding proteins directed against immune cell receptors and autoantigens
|
|
EP3055298B1
(en)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
|
US10376582B2
(en)
|
2013-10-16 |
2019-08-13 |
Outlook Therapeutics, Inc. |
Buffer formulations for enhanced antibody stability
|
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
|
US20150203592A1
(en)
|
2013-12-02 |
2015-07-23 |
Abbvie Inc. |
Compositions and methods for treating osteoarthritis
|
|
CN103965357B
(zh)
|
2013-12-31 |
2016-08-17 |
嘉和生物药业有限公司 |
一种抗人rankl抗体
|
|
WO2015131078A1
(en)
|
2014-02-27 |
2015-09-03 |
Biogen Ma Inc. |
Method of assessing risk of pml
|
|
PT3116891T
(pt)
|
2014-03-10 |
2020-05-18 |
Richter Gedeon Nyrt |
Purificação de imunoglobulina utilizando passos de pré-limpeza
|
|
CN110845616A
(zh)
|
2014-03-21 |
2020-02-28 |
艾伯维公司 |
抗-egfr抗体及抗体药物偶联物
|
|
AR099625A1
(es)
*
|
2014-03-21 |
2016-08-03 |
Lilly Co Eli |
Anticuerpos de il-21
|
|
US10688187B2
(en)
|
2014-04-02 |
2020-06-23 |
Intas Pharmaceuticals Ltd. |
Liquid pharmaceutical composition of adalimumab
|
|
EP3139949B1
(en)
|
2014-05-08 |
2020-07-29 |
Phasebio Pharmaceuticals, Inc. |
Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis
|
|
EP2946766B1
(en)
|
2014-05-23 |
2016-03-02 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
ES2600488T3
(es)
|
2014-05-23 |
2017-02-09 |
Ares Trading S.A. |
Composición farmacéutica líquida
|
|
ES2607489T3
(es)
|
2014-05-23 |
2017-03-31 |
Ares Trading S.A. |
Composición farmacéutica líquida
|
|
FR3022462B1
(fr)
*
|
2014-06-18 |
2018-04-27 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Composition orale d'anticorps anti-tnfalpha
|
|
US20170183376A1
(en)
|
2014-06-24 |
2017-06-29 |
Insight Biopharmaceuticals Ltd. |
Methods of purifying antibodies
|
|
WO2016000813A1
(en)
*
|
2014-06-30 |
2016-01-07 |
Merck Patent Gmbh |
Anti-tnfa antibodies with ph-dependent antigen binding
|
|
US20170226552A1
(en)
|
2014-07-03 |
2017-08-10 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
|
|
US20160185848A1
(en)
|
2014-07-09 |
2016-06-30 |
Abbvie Inc. |
Methods for modulating the glycosylation profile of recombinant proteins using sugars
|
|
US10755801B2
(en)
|
2014-07-11 |
2020-08-25 |
Iogenetics, Llc |
Identifying peptides having T-cell-exposed motifs with known frequency of occurrence in a reference database
|
|
WO2016036918A1
(en)
*
|
2014-09-03 |
2016-03-10 |
Boehringer Ingelheim International Gmbh |
Compound targeting il-23a and tnf-alpha and uses thereof
|
|
US10435464B1
(en)
|
2014-09-05 |
2019-10-08 |
Coherus Biosciences, Inc. |
Methods for making recombinant proteins
|
|
HUP1400510A1
(hu)
|
2014-10-28 |
2016-05-30 |
Richter Gedeon Nyrt |
Gyógyászati TNFalfa ellenes antitest készítmény
|
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
|
US20170360929A1
(en)
|
2014-12-23 |
2017-12-21 |
Pfizer Inc. |
Stable aqueous antibody formulation for anti tnf alpha antibodies
|
|
EP3085709B1
(en)
|
2014-12-28 |
2019-08-21 |
Genor Biopharma Co., Ltd |
Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
|
|
WO2016118707A1
(en)
|
2015-01-21 |
2016-07-28 |
Oncobiologics, Inc. |
Modulation of charge variants in a monoclonal antibody composition
|
|
EP3053572A1
(en)
|
2015-02-06 |
2016-08-10 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
WO2016130518A2
(en)
|
2015-02-09 |
2016-08-18 |
Phasebio Pharmaceuticals, Inc. |
Methods and compositions for treating muscle disease and disorders
|
|
CN105777905B
(zh)
*
|
2015-03-24 |
2019-06-25 |
广东东阳光药业有限公司 |
一种全人源抗TNF-α单克隆抗体及其应用
|
|
EP3078675A1
(en)
|
2015-04-10 |
2016-10-12 |
Ares Trading S.A. |
Induction dosing regimen for the treatment of tnf alpha mediated disorders
|
|
WO2016179469A1
(en)
*
|
2015-05-07 |
2016-11-10 |
Abbvie Inc. |
Methods and compositions for diagnosing and treating inflammatory bowel disease
|
|
UY36692A
(es)
|
2015-05-29 |
2016-12-30 |
Abbvie Inc |
Anticuerpos anti-cd40 y usos de los mismos
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
FR3038517B1
(fr)
|
2015-07-06 |
2020-02-28 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Utilisation de fragments fc modifies en immunotherapie
|
|
HU231463B1
(hu)
|
2015-08-04 |
2024-01-28 |
Richter Gedeon Nyrt. |
Módszer rekombináns proteinek galaktóz tartalmának növelésére
|
|
US11229702B1
(en)
|
2015-10-28 |
2022-01-25 |
Coherus Biosciences, Inc. |
High concentration formulations of adalimumab
|
|
US11583584B1
(en)
|
2015-10-28 |
2023-02-21 |
Coherus Biosciences, Inc. |
Stable protein compositions and methods of their use
|
|
GB201522394D0
(en)
|
2015-12-18 |
2016-02-03 |
Ucb Biopharma Sprl |
Antibodies
|
|
AU2017213775A1
(en)
|
2016-02-03 |
2018-08-16 |
Outlook Therapeutics, Inc. |
Buffer formulations for enhanced antibody stability
|
|
US10465003B2
(en)
|
2016-02-05 |
2019-11-05 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
|
|
CN109153718B
(zh)
*
|
2016-03-17 |
2022-02-08 |
努玛治疗有限公司 |
抗TNFα抗体及其功能片段
|
|
ES2836349T3
(es)
*
|
2016-03-17 |
2021-06-24 |
Tillotts Pharma Ag |
Anticuerpos anti-TNF-alfa y fragmentos funcionales de los mismos
|
|
JP2019513737A
(ja)
|
2016-04-08 |
2019-05-30 |
ギリアード サイエンシーズ， インコーポレイテッド |
がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法
|
|
WO2017184880A1
(en)
|
2016-04-20 |
2017-10-26 |
Coherus Biosciences, Inc. |
A method of filling a container with no headspace
|
|
WO2017189805A1
(en)
|
2016-04-27 |
2017-11-02 |
Abbvie Inc. |
Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
|
|
ES2877548T3
(es)
|
2016-06-02 |
2021-11-17 |
Abbvie Inc |
Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
|
|
JP2019521975A
(ja)
|
2016-06-08 |
2019-08-08 |
アッヴィ・インコーポレイテッド |
抗ｅｇｆｒ抗体薬物コンジュゲート
|
|
WO2017214339A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
|
WO2017214456A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
|
CN109563167A
(zh)
|
2016-06-08 |
2019-04-02 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
|
PL3458479T4
(pl)
|
2016-06-08 |
2021-07-26 |
Abbvie Inc. |
Przeciwciała anty-b7-h3 i koniugaty przeciwciało-lek
|
|
AU2017277422A1
(en)
|
2016-06-08 |
2019-01-03 |
Abbvie Inc. |
Anti-EGFR antibody drug conjugates
|
|
WO2017218698A1
(en)
|
2016-06-15 |
2017-12-21 |
Sutro Biopharma, Inc. |
Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
|
|
WO2018018613A1
(zh)
|
2016-07-29 |
2018-02-01 |
广东东阳光药业有限公司 |
一种提高抗体纯度的细胞培养基和培养方法
|
|
US12097292B2
(en)
|
2016-08-28 |
2024-09-24 |
Mapi Pharma Ltd. |
Process for preparing microparticles containing glatiramer acetate
|
|
HRP20250396T1
(hr)
|
2016-08-31 |
2025-05-23 |
Mapi Pharma Ltd. |
Depo sustavi koji sadrže glatiramer acetat
|
|
WO2018045258A1
(en)
*
|
2016-09-02 |
2018-03-08 |
The University Of Chicago |
TREATMENT OF TNF-alpha CYTOTOXICITY
|
|
EP3512875A2
(en)
*
|
2016-09-15 |
2019-07-24 |
Quadrucept Bio Limited |
Multimers, tetramers&octamers
|
|
CN110383068A
(zh)
|
2016-10-03 |
2019-10-25 |
雅培实验室 |
评估患者样品中uch-l1状态的改进方法
|
|
WO2018075408A1
(en)
|
2016-10-17 |
2018-04-26 |
Alexion Pharmaceuticals, Inc. |
Methods of treating acute myeloid leukemia (aml) with combinations of anti-cd200 antibodies, cytarabine, and daunorubicin
|
|
AU2017345490B2
(en)
|
2016-10-21 |
2022-07-07 |
Amgen Inc. |
Pharmaceutical formulations and methods of making the same
|
|
WO2018102594A1
(en)
|
2016-12-01 |
2018-06-07 |
Alexion Pharmaceuticals, Inc. |
Methods of treating solid tumors with anti-cd200 antibodies
|
|
EP3551047A1
(en)
|
2016-12-07 |
2019-10-16 |
Progenity, Inc. |
Gastrointestinal tract detection methods, devices and systems
|
|
TW201834711A
(zh)
|
2016-12-14 |
2018-10-01 |
美商寶珍那提公司 |
以tnf抑制劑治療胃腸道疾病
|
|
JP7350313B2
(ja)
|
2016-12-16 |
2023-09-26 |
ブルーフィン バイオメディシン， インコーポレイテッド |
抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
|
|
EP3824906A1
(en)
|
2016-12-21 |
2021-05-26 |
Amgen Inc. |
Anti-tnf alpha antibody formulations
|
|
JOP20190162A1
(ar)
|
2016-12-30 |
2019-06-27 |
Biocad Joint Stock Co |
تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
|
|
AU2018207367B2
(en)
|
2017-01-11 |
2024-02-15 |
Celltrion Inc. |
Stable Liquid Formula
|
|
AR110755A1
(es)
|
2017-01-20 |
2019-05-02 |
Genzyme Corp |
Anticuerpos dirigidos a hueso
|
|
TW202506185A
(zh)
|
2017-01-20 |
2025-02-16 |
法商賽諾菲公司 |
抗TGF-β抗體及其用途
|
|
IL268007B2
(en)
|
2017-01-30 |
2025-05-01 |
Janssen Biotech Inc |
Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
|
|
AU2017398101B2
(en)
|
2017-02-07 |
2025-02-06 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
|
|
US11608357B2
(en)
|
2018-08-28 |
2023-03-21 |
Arecor Limited |
Stabilized antibody protein solutions
|
|
EP3372241A1
(en)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
EP3372242A1
(en)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
CA3052513A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
|
AU2018242998B2
(en)
|
2017-03-26 |
2023-11-02 |
Mapi Pharma Ltd. |
Glatiramer depot systems for treating progressive forms of multiple sclerosis
|
|
WO2018184692A1
(en)
|
2017-04-07 |
2018-10-11 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
JP7344797B2
(ja)
|
2017-04-15 |
2023-09-14 |
アボット・ラボラトリーズ |
早期バイオマーカーを使用する、ヒト対象における外傷性脳損傷の、超急性の診断及び決定の一助となるための方法
|
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
|
AU2018272054B2
(en)
|
2017-05-25 |
2024-10-31 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
|
AU2018275236B2
(en)
|
2017-05-30 |
2024-11-07 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I
|
|
CA3068041C
(en)
|
2017-07-03 |
2024-06-25 |
Abbott Laboratories |
Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
|
|
WO2019067499A1
(en)
|
2017-09-27 |
2019-04-04 |
Alexion Pharmaceuticals, Inc. |
BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
|
|
AU2018374634A1
(en)
|
2017-12-01 |
2020-05-28 |
Abbvie Inc. |
Glucocorticoid receptor agonist and immunoconjugates thereof
|
|
CN109879962B
(zh)
*
|
2017-12-06 |
2022-10-11 |
北京科立思维生物科技有限公司 |
抗tnf单链抗体、抗il-6单链抗体及其融合蛋白及其应用
|
|
JP7344801B2
(ja)
|
2017-12-09 |
2023-09-14 |
アボット・ラボラトリーズ |
グリア原線維性酸性タンパク質（ｇｆａｐ）及び／又はユビキチンカルボキシ末端ヒドロラーゼｌ１（ｕｃｈ－ｌ１）を使用する、整形外科損傷を負っており、軽度外傷性脳損傷（ｔｂｉ）などの頭部への損傷を負ったか又は負った可能性がある対象についての診断及び査定の一助となるための方法
|
|
US11016105B2
(en)
|
2017-12-09 |
2021-05-25 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
|
|
US11802154B2
(en)
|
2017-12-20 |
2023-10-31 |
Alexion Pharmaceuticals, Inc. |
Humanized anti-CD200 antibodies and uses thereof
|
|
WO2019126133A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals, Inc. |
Liquid formulations of anti-cd200 antibodies
|
|
CA3093772C
(en)
|
2018-03-12 |
2024-04-16 |
Zoetis Services Llc |
Anti-ngf antibodies and methods thereof
|
|
WO2019190877A1
(en)
|
2018-03-26 |
2019-10-03 |
Alexion Pharmaceuticals, Inc. |
High throughput method for measuring the protease activity of complement c3 convertase
|
|
US12037398B2
(en)
|
2018-06-04 |
2024-07-16 |
Biogen Ma Inc. |
Anti-VLA-4 antibodies having reduced effector function
|
|
WO2019246313A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
|
CN112654350A
(zh)
|
2018-07-03 |
2021-04-13 |
诺华股份有限公司 |
使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法
|
|
WO2020076849A1
(en)
|
2018-10-11 |
2020-04-16 |
The Scripps Research Institute |
Antibody compounds with reactive arginine and related antibody drug conjugates
|
|
EP3870168A1
(en)
|
2018-10-24 |
2021-09-01 |
Novartis AG |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
KR20210088611A
(ko)
|
2018-11-05 |
2021-07-14 |
베이징 한미 파마슈티컬 컴퍼니 리미티드 |
항TNFα/항IL-17A 천연항체 구조 형태의 헤테로다이머 이중특이성 항체 및 그 제조방법
|
|
HU231514B1
(hu)
|
2018-11-07 |
2024-07-28 |
Richter Gedeon Nyrt. |
Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
|
|
EP3880666B1
(en)
|
2018-11-13 |
2023-06-28 |
Novartis AG |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
WO2020102098A1
(en)
|
2018-11-13 |
2020-05-22 |
Novartis Inflammasome Research, Inc. |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
CN116726362A
(zh)
|
2018-11-19 |
2023-09-12 |
比奥拉治疗股份有限公司 |
用生物治疗剂治疗疾病的方法和装置
|
|
WO2020118011A1
(en)
|
2018-12-06 |
2020-06-11 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
|
ES3031988T3
(en)
|
2018-12-25 |
2025-07-14 |
Beijing Baishihekang Pharmaceutical Tech Bsjpharma Co Ltd |
Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof
|
|
WO2020154321A1
(en)
|
2019-01-22 |
2020-07-30 |
Novartis Inflammasome Research, Inc. |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
HU231498B1
(hu)
|
2019-04-04 |
2024-05-28 |
Richter Gedeon Nyrt |
Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelőző flokkulálás alkalmazásával
|
|
KR102323342B1
(ko)
*
|
2019-04-26 |
2021-11-08 |
주식회사 와이바이오로직스 |
IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
|
|
CA3138241A1
(en)
|
2019-05-23 |
2020-11-26 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
|
|
WO2021002887A1
(en)
|
2019-07-02 |
2021-01-07 |
Novartis Inflammasome Research, Inc. |
Gut-targeted nlrp3 antagonists and their use in therapy
|
|
WO2021005607A1
(en)
*
|
2019-07-09 |
2021-01-14 |
National Institute For Biotechnology In The Negev Ltd. |
Antibodies with reduced immunogenicity
|
|
CN115666704B
(zh)
|
2019-12-13 |
2025-09-26 |
比特比德科有限责任公司 |
用于将治疗剂递送至胃肠道的可摄取装置
|
|
FR3104582A1
(fr)
|
2019-12-17 |
2021-06-18 |
Commissariat A L'energie Atomique Et Aux Energies Alternatives |
Variants de l’adalimumab au potentiel immunogène réduit
|
|
CA3167027A1
(en)
|
2020-02-05 |
2021-08-12 |
Larimar Therapeutics, Inc. |
Tat peptide binding proteins and uses thereof
|
|
EP4114852A1
(en)
|
2020-03-03 |
2023-01-11 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
|
WO2021211331A1
(en)
|
2020-04-13 |
2021-10-21 |
Abbott Point Of Care Inc. |
METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
|
|
KR20230012539A
(ko)
|
2020-05-13 |
2023-01-26 |
디스크 메디슨, 인크. |
골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
|
|
EP4596046A3
(en)
|
2020-05-21 |
2025-10-22 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
|
|
KR20230042301A
(ko)
|
2020-08-04 |
2023-03-28 |
애벗트 라보라토리이즈 |
샘플에서 sars-cov-2 단백질을 검출하기 위한 개선된 방법 및 키트
|
|
CN111944052B
(zh)
*
|
2020-08-26 |
2022-02-11 |
中国药科大学 |
抗TNF-α/PD-1双特异性抗体及其应用
|
|
CN112010970B
(zh)
*
|
2020-10-30 |
2021-01-12 |
迈威(上海)生物科技股份有限公司 |
一种去除重组表达抗体聚体和降解产物的方法
|
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
|
CA3198161A1
(en)
|
2020-12-01 |
2022-06-09 |
Beth MCQUISTON |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
|
US11672929B2
(en)
|
2020-12-02 |
2023-06-13 |
Breathe Restore, Inc. |
Product delivery devices and methods
|
|
WO2022123293A1
(ko)
|
2020-12-09 |
2022-06-16 |
에이치케이이노엔 주식회사 |
항 OX40L 항체, 항 OX40L 및 항 TNFα 이중 특이성 항체 및 이들의 용도
|
|
CA3202331A1
(en)
*
|
2020-12-18 |
2022-06-23 |
Stephanie A. Pierce |
Tnf alpha and ngf antibodies for veterinary use
|
|
WO2022147147A1
(en)
|
2020-12-30 |
2022-07-07 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
|
US12180521B2
(en)
*
|
2021-02-19 |
2024-12-31 |
Theripion, Inc. |
Paraoxonase fusion polypeptides and related compositions and methods
|
|
AU2022264509A1
(en)
|
2021-04-27 |
2023-12-14 |
Generation Bio Co. |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
|
EP4329884A1
(en)
|
2021-04-27 |
2024-03-06 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
EP4341699A1
(en)
|
2021-05-18 |
2024-03-27 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
|
EP4528280A3
(en)
|
2021-06-14 |
2025-07-02 |
Abbott Laboratories |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
|
AU2022298665A1
(en)
*
|
2021-06-22 |
2024-01-04 |
University Of Virginia Patent Foundation |
Compositions and methods for detecting and regulating fibronectin-integrin interactions and signaling
|
|
CN120463762A
(zh)
|
2021-08-26 |
2025-08-12 |
映恩生物科技(上海)有限公司 |
一种甾体化合物及其缀合物
|
|
CN118715440A
(zh)
|
2021-08-31 |
2024-09-27 |
雅培实验室 |
诊断脑损伤的方法和系统
|
|
AU2022339759A1
(en)
|
2021-08-31 |
2024-03-07 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
|
CA3232176A1
(en)
|
2021-09-30 |
2023-04-06 |
Beth MCQUISTON |
Methods and systems of diagnosing brain injury
|
|
JP2025503439A
(ja)
|
2021-12-17 |
2025-02-04 |
アボット・ラボラトリーズ |
血液試料におけるｕｃｈ－ｌ１、ｇｆａｐ及び他のバイオマーカーを決定するためのシステム及び方法
|
|
AU2023216317A1
(en)
|
2022-02-04 |
2024-09-05 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
|
KR20240161965A
(ko)
|
2022-03-14 |
2024-11-13 |
제너레이션 바이오 컴퍼니 |
이종 프라임 부스트 백신 조성물 및 사용 방법
|
|
JP2025526279A
(ja)
*
|
2022-06-28 |
2025-08-13 |
アダフレ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニー |
抗ＴＮＦα抗体および組成物
|
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
|
CN116903738A
(zh)
*
|
2022-08-02 |
2023-10-20 |
北京绿竹生物技术股份有限公司 |
一种低甘露糖型抗人肿瘤坏死因子-α单抗及其用途
|
|
CN120435285A
(zh)
|
2022-09-07 |
2025-08-05 |
Mdx管理有限责任公司 |
用于治疗癌症的shp-1抑制剂
|
|
CA3265992A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Lab |
BIOMARKERS AND METHODS FOR DIFFERENTIATING BETWEEN MILD AND VERY MILD TRAUMATIC BRAIN INJURY
|
|
KR20250141124A
(ko)
|
2022-11-02 |
2025-09-26 |
엠디엑스 메니지먼트 엘엘씨 |
암 치료를 위한 티로신 키나제 억제제와 염증 촉진제의 조합
|
|
TW202444339A
(zh)
|
2023-03-17 |
2024-11-16 |
美商Ｍｄｘ管理有限責任公司 |
用於改善療法不良反應之組合物及方法
|
|
WO2024211475A1
(en)
|
2023-04-04 |
2024-10-10 |
Abbott Laboratories |
Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
|
|
WO2024226971A1
(en)
|
2023-04-28 |
2024-10-31 |
Abbott Point Of Care Inc. |
Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
|
|
WO2025038745A1
(en)
|
2023-08-16 |
2025-02-20 |
Mdx Management Llc |
Compositions and methods for activating immune cells
|
|
WO2025188920A1
(en)
|
2024-03-06 |
2025-09-12 |
Mdx Management Llc |
Local application of agents inhibiting tyrosine kinase or shp-1 signaling
|
|
WO2025238106A1
(en)
|
2024-05-15 |
2025-11-20 |
M6P Therapeutics (Switzerland) GmbH |
Lysosome-targeting degradation fusion design
|